soul trial oral semaglutide cardiovascular outcomes 2024 nejm results 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Canadian Perspectives 2025 Whiteboard on

If you notice symptoms like rash, itching, swelling, or hives, stop taking the medication and seek medical attention promptly

These tend to be mild and short-lived

A follow-up study confirmed that individuals with inherently higher calories consumed to reach satiation (CTS), that is impaired satiation, prior to treatment displayed greater weight loss in response to phentermine-topiramate

Cystine crystals induce ROS production through increased disulfide stress and promote oxidative stress reactions within cancer cells [48]

But GLP-1 fatigue often feels heavier when sleep quality is already poor

Aroda VR, Bauer R, Christiansen E, et al